BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foersch S, Eckstein M, Wagner DC, Gach F, Woerl AC, Geiger J, Glasner C, Schelbert S, Schulz S, Porubsky S, Kreft A, Hartmann A, Agaimy A, Roth W. Deep learning for diagnosis and survival prediction in soft tissue sarcoma. Ann Oncol 2021;32:1178-87. [PMID: 34139273 DOI: 10.1016/j.annonc.2021.06.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Schulz S, Woerl AC, Jungmann F, Glasner C, Stenzel P, Strobl S, Fernandez A, Wagner DC, Haferkamp A, Mildenberger P, Roth W, Foersch S. Multimodal Deep Learning for Prognosis Prediction in Renal Cancer. Front Oncol 2021;11:788740. [PMID: 34900744 DOI: 10.3389/fonc.2021.788740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Schrammen PL, Ghaffari Laleh N, Echle A, Truhn D, Schulz V, Brinker TJ, Brenner H, Chang-Claude J, Alwers E, Brobeil A, Kloor M, Heij LR, Jäger D, Trautwein C, Grabsch HI, Quirke P, West NP, Hoffmeister M, Kather JN. Weakly supervised annotation-free cancer detection and prediction of genotype in routine histopathology. J Pathol 2021. [PMID: 34561876 DOI: 10.1002/path.5800] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ngo C, Postel-vinay S. Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments. Biomedicines 2022;10:650. [DOI: 10.3390/biomedicines10030650] [Reference Citation Analysis]
4 Choi S, Cho SI, Ma M, Park S, Pereira S, Aum BJ, Shin S, Paeng K, Yoo D, Jung W, Ock C, Lee S, Choi Y, Chung J, Mok TS, Kim H, Kim S. Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response. European Journal of Cancer 2022;170:17-26. [DOI: 10.1016/j.ejca.2022.04.011] [Reference Citation Analysis]
5 Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol 2022. [PMID: 35039679 DOI: 10.1038/s41571-021-00597-8] [Reference Citation Analysis]